



AstraZeneca Pharma India Limited

Regd. Office : 'Avishkar' Off Bellary Road, Hebbal, Bangalore 560 024

FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30 JUNE 2009

Rs in lakhs (except for number of shares)						
Sl. No.	Particulars	3 Months Ended 30.06.2009  (Unaudited)	3 Months Ended 30.06.2008  (Unaudited)	Half Year Ended 30.06.2009  (Unaudited)	Half Year Ended 30.06.2008  (Unaudited)	Previous Accounting Year Ended 31.12.2008 (Audited)
1	(a) Net sales (net of excise duty)	9,585.79	8,821.96	17,329.75	15,788.04	33,976.85
	(b) Other operating income:					
	- Service income	336.57	485.34	615.64	891.52	1,449.62
2	Expenditure					
	(a) (Increase) / decrease in stock-in-trade and work-in-progress	(86.92)	282.75	(93.84)	(289.64)	(931.77)
	(b) Consumption of raw materials and packing materials	935.76	1,049.69	1,754.85	1,995.48	4,296.86
	(c) Purchase of traded goods	2,107.27	1,154.46	3,802.60	2,848.05	6,585.62
	(d) Employees cost	2,117.30	1,601.66	4,244.75	3,080.85	6,217.28
	(e) Depreciation	151.88	146.88	298.08	295.46	687.63
	(f) Other expenditure	2,407.20	1,937.12	4,713.42	4,039.21	8,034.52
	(g) Total	7,632.49	6,172.56	14,719.86	11,969.41	24,890.14
3	Profit from operations before other income, interest & exceptional items (1-2)	2,289.87	3,134.74	3,225.53	4,710.15	10,536.33
4	Other income	114.30	295.99	388.50	554.62	1,387.57
5	Profit before interest & exceptional items (3+4)	2,404.17	3,430.73	3,614.03	5,264.77	11,923.90
6	Interest	-	123.29	13.70	234.25	486.30
7	Profit after interest but before exceptional items (5-6)	2,404.17	3,307.44	3,600.33	5,030.52	11,437.60
8	Exceptional items	-	-	-	-	-
9	Profit from ordinary activities before tax (7+8)	2,404.17	3,307.44	3,600.33	5,030.52	11,437.60
10	Tax expense	875.74	1,176.46	1,344.45	1,785.43	4,054.08
11	Net profit from ordinary activities after tax (9-10)	1,528.43	2,130.98	2,255.88	3,245.09	7,383.52
12	Extraordinary Item	-	-	-	-	-
13	Net profit for the period (11-12)	1,528.43	2,130.98	2,255.88	3,245.09	7,383.52
14	Paid-up equity share capital (Face value of Rs 2 per equity share)	500.00	500.00	500.00	500.00	500.00
15	Reserves excluding revaluation reserves as per the balance sheet of previous accounting year					11,114.97
16	Basic and diluted earnings (Rs) per share (not annualised)	6.11	8.52	9.02	12.98	29.53
17	Public shareholding					
	- Number of shares	2,500,050	2,500,050	2,500,050	2,500,050	2,500,050
	- Percentage of shareholding	10.0002%	10.0002%	10.0002%	10.0002%	10.0002%
18	Promoters and promoter group shareholding					
	a) Pledged / Encumbered					
	- Number of shares	-	-	-	-	-
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	-	-	-	-	-
	- Percentage of shares (as a % of the total share capital of the Company)	-	-	-	-	-
	b) Non-encumbered					
	- Number of shares	22,499,950		22,499,950		
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	100%		100%		
	- Percentage of shares (as a % of the total share capital of the Company)	89.9998%		89.9998%		

Notes:

- The above statement of financial results was reviewed by the Audit Committee and having been recommended for approval, was approved by the Board of Directors of the Company at their meeting held on 27 July 2009.
- The Company has embarked on a long term growth strategy to significantly enhance its market presence by launch of new products to expand its product portfolio, coupled with consequential expansion of its field force. Towards this strategy the Company has made considerable investments in expanding its field force in the first half of FY 2009, which has resulted in increased manpower costs. This in turn has impacted the profitability for the current period as compared to the corresponding period of FY 2008.
- Status of investor complaints : a) Pending as on 1 April 2009 - NIL b) Received during the quarter - 8 c) Disposed off during the quarter - 8 d) Pending as on 30 June 2009 - NIL.
- The Board of Directors, at their meeting held on 12 January 2008, pursuant to the scheme of arrangement sanctioned by the Honourable High Court of Karnataka on 7 July 2007 and subsequent approval accorded by the Reserve Bank of India on 11 December 2007, allotted 8% secured fully paid-up redeemable non-convertible bonus debentures from the general reserve, in the ratio of one debenture of the face value of Rs 25 each for every equity share held by the shareholders of the Company as on 11 January 2008. The bonus debentures were listed on the Bangalore Stock Exchange Limited, Bombay Stock Exchange Limited and National Stock Exchange of India Limited. The bonus debentures and the interest thereon were redeemed on 11 January 2009.
- Comparative information for promoter and promoter group shareholding has not been disclosed as the disclosure requirements are effective from quarter ended 31 March 2009.
- Previous period figures have been regrouped / reclassified, wherever necessary to conform to the current period's presentation.

Segment Wise Revenue, Results And Capital Employed

Rs in lakhs						
Sl. No.	Particulars	3 Months Ended 30.06.2009  (Unaudited)	Corresponding 3 Months Ended in the previous Year 30.06.2008 (Unaudited)	6 Months Ended 30.06.2009  (Unaudited)	Corresponding 6 Months Ended in the previous Year 30.06.2008 (Unaudited)	Previous Accounting Year Ended 31.12.2008 (Audited)
1	Segment Revenue					
	(a) Healthcare	9,593.39	8,841.72	17,342.79	15,815.10	34,133.87
	(b) Clinical Trials Service	336.57	485.34	615.64	891.52	1,449.62
	Total	9,929.96	9,327.06	17,958.43	16,706.62	35,583.49
	Less: Inter-segment Revenue	-	-	-	-	-
	Net Income From Operations	9,929.96	9,327.06	17,958.43	16,706.62	35,583.49
2	Segment Results					
	Profit before Tax and interest					
	(a) Healthcare	2,292.40	3,152.21	3,229.15	4,732.52	10,681.03
	(b) Clinical Trials Service	5.07	2.29	9.42	4.69	12.32
	Total	2,297.47	3,154.50	3,238.57	4,737.21	10,693.35
	Add: Other Income	106.70	276.23	375.46	527.56	1,230.55
	Less: Interest	-	123.29	13.70	234.25	486.30
	Total Profit Before Tax	2,404.17	3,307.44	3,600.33	5,030.52	11,437.60
3	Capital Employed					
	(a) Healthcare	8,769.16	8,187.53	8,769.16	8,187.53	8,816.80
	(b) Clinical Trials Service	(524.15)	(105.37)	(524.15)	(105.37)	(360.29)
	(c) Unallocated	5,625.84	3,781.69	5,625.84	3,781.69	3,158.46
	Total	13,870.85	11,863.85	13,870.85	11,863.85	11,614.97

Note: Certain assets and liabilities of the Healthcare segment are interchangeably used for Clinical Trials Service segment for limited purposes. Identification of such assets and liabilities is not feasible. Hence, such assets have not been allocated to any segment.

By Order of the Board of Directors  
For AstraZeneca Pharma India Limited

Place : Bangalore  
Dated : 27 July 2009

Anandh Balasundaram  
Managing Director

16cm(w) x 45cm(h)